Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies
October 16, 2024 14:48 ET
|
Spherix Global Insights
EXTON, PA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing demand for...
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
July 18, 2024 10:05 ET
|
Spherix Global Insights
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
March 22, 2024 10:14 ET
|
Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
December 07, 2023 12:01 ET
|
Spherix Global Insights
Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call,...
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
November 30, 2023 10:59 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra
November 13, 2023 09:22 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the...
Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
April 26, 2023 09:03 ET
|
Corza Medical Inc.
WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company...
Federal Lawsuit Funded by We The Patriots USA Filed Against Takeda Pharmaceuticals
November 18, 2022 08:57 ET
|
We The Patriots USA, Inc.
BOSTON, Nov. 18, 2022 (GLOBE NEWSWIRE) -- A federal lawsuit was filed today in the U.S. District Court of Massachusetts against Takeda Pharmaceuticals, alleging religious discrimination. A group of...
Antithrombin Market is estimated to be US$ 849.87 million by 2030 with a CAGR of 4.3% during the forecast period 2030 - By PMI
September 15, 2022 08:54 ET
|
PMI
Covina, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The protein which blocks thrombin is called as antithrombin. Antithrombin is the glycoprotein which is synthesized by the liver. Antithrombin inhibits the...
Societal CDMO Appoints Elena Cant to Board of Directors
September 08, 2022 07:00 ET
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...